I don’t anticipate the cost of DCVax-L, after approval, to be £250k… more like £150k. And once Flaskworks is implemented, the price lessen by even more.
Additionally, I believe the company intends to sell the first four or so vaccines for use over a month or two, instead of all at once when the doses have been manufactured. The remaining doses would then be sold to the patient according to the dosage schedule. That is how I believe the company intends to sell the vaccine… although I could be wrong.
Such a distribution and pricing arrangement would help to make DCVax-L more affordable to the U.K. govt., IMO.